Current Analysis of Clinical Trials of Weight Control Drugs
Objective:This study analyzes the research status and trends of weight control drug clinical trials in China from 2018 to 2023,and provides guidance for future research.Methods:Detailed information on registered weight control drug clinical trials in Chi-na was retrieved and collected from the Chinese Clinical Trial Registry and the Information Disclosure Platform for Drug Clinical Stud-ies.Analysis was conducted on the trends in weight control drug clinical trials,registration characteristics,mechanisms of action,and geographical locations of leading institutions.Results:The number of registered weight control drug clinical trials reached its highest point in 2023.PhaseⅠ,Ⅱ,andⅢclinical trials accounted for 87.9%(51/58)of the trials,with parallel,randomized,and double-blind designs being predominant.In terms of target mechanisms,glucagon-like peptide-1(GLP-1)receptor agonists ranked first in the number of single-target trials(27/58).Leading institutions conducting drug clinical trials were primarily located in Beijing(27/58),Shanghai(6/58),and Changsha(5/58).Conclusion:The number of weight control drug clinical trials is showing an upward trend,par-ticularly in the development of clinical trials focusing on single and combination therapies targeting GLP-1 receptor agonists.
NETL
NSTL
万方数据
